Literature DB >> 1716430

Clinical applications of serum tumor markers.

S E Bates1.   

Abstract

The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. Tumor markers have five potential uses in patient care: They can be used for screening, for diagnosis, for establishing prognosis, for monitoring treatment, and for detecting relapse. The value of a marker in a given setting depends on two marker-related characteristics--sensitivity and specificity. The value of a marker in a particular malignancy also depends on the effectiveness of therapy for the malignancy. Tumor markers have been used to screen for occult cancer but have proved to be valuable only in selected cancers. As diagnostic tools, tumor markers have limitations: Nearly all markers can be elevated in benign disorders, and most markers are not elevated in the early stages of malignancy. Extreme marker elevation often indicates a poor prognosis and in some malignancies can indicate the need for more aggressive treatment. Tumor markers have their greatest value when used to monitor therapy in patients with widespread cancer. Nearly all markers show some correlation with the clinical course of disease, with marker elevation in any stage declining to normal after a curative intervention. Recurrent disease can be accompanied by increased marker levels, but markers can detect an occult recurrence in only a few diseases, thereby facilitating a second attempt at cure. Although it seems unlikely that an ideal tumor marker will be identified for every malignancy, several workable markers are already available. Increasing our knowledge about the capabilities and limitations of existing markers will enable us to use them judiciously in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716430     DOI: 10.7326/0003-4819-115-8-623

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

1.  Carbohydrate-antigen-125 levels predict hospital stay duration and adverse events at long-term follow-up in Takotsubo cardiomyopathy.

Authors:  Francesco Santoro; Armando Ferraretti; Francesco Musaico; Luigi Di Martino; Nicola Tarantino; Riccardo Ieva; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Intern Emerg Med       Date:  2016-02-01       Impact factor: 3.397

2.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma.

Authors:  Nabil Mohie Abdel-Hamid; M M Abouzied; M H Nazmy; M A Fawzy; A S Gerges
Journal:  Tumour Biol       Date:  2015-09-19

4.  Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.

Authors:  M van de Pol; A Twijnstra; G P ten Velde; P P Menheere
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients.

Authors:  Shin-ichi Kosugi; Tadashi Nishimaki; Tatsuo Kanda; Satoru Nakagawa; Manabu Ohashi; Katsuyoshi Hatakeyama
Journal:  World J Surg       Date:  2004-06-04       Impact factor: 3.352

Review 6.  Critical evaluation of diagnostic aids for the detection of oral cancer.

Authors:  Mark W Lingen; John R Kalmar; Theodore Karrison; Paul M Speight
Journal:  Oral Oncol       Date:  2007-09-06       Impact factor: 5.337

7.  The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.

Authors:  Wenfeng Li; Weiwei Yin; Rongying Ou; Ting Chen; Lingling Xiong; Dezhi Cheng; Deyao Xie; Xiangwu Zheng; Yunsheng Xu; Liang Zhao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

8.  Plasma and tumor prolactin in colorectal cancer patients.

Authors:  Y Ilan; O Sibirsky; N Livni; O Gofrit; V Barack; E Goldin
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

9.  Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.

Authors:  Ercan Varol; Mehmet Ozaydin; Ahmet Altinbas; Suleyman M Aslan; Abdullah Dogan; Ozkan Dede
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

10.  Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.

Authors:  A J Gross; M Wolff; J Fandrey; W D Miersch; K P Dieckmann; W Jelkmann
Journal:  Clin Investig       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.